For more information call (888) LUHS-888.
Patients with the following criteria may be eligible:
Women with histologically confirmed hormone receptor positive invasive carcinoma of the breast with no evidence of metastatic disease (M0)
Completed mastectomy or breast-sparing surgery
Must currently be taking an aromatase inhibitor for at least 21 days, but no longer than 36 months
Must have aromatase-inhibitor-associated musculoskeletal symptoms that began or increased after starting AI therapy
ECOG PS of 0-2 with good organ function
Must not require SSRIs or SNRIs
Must not have a current primary psychiatric diagnosis, suicidal ideation, history of bipolar disorder, seizure disorder, alcohol or other substance abuse or dependence
Must not have uncontrolled narrow-angle glaucoma or clinically significant coagulation disorder
The goal of this study is to assess the effects, good and/or bad, of the medication duloxetine compared with a placebo (contains no active ingredient) on joint pain that is associated with taking aromatase inhibitors.